Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/87264
Title: | Anticoagulation control with the point-of-care INR : a retrospective pre-/post-analysis |
Authors: | Riva, Nicoletta Meli, Stephanie Borg Xuereb, Christian Ageno, Walter Makris, Michael Gatt, Alexander Vella, Kevin |
Keywords: | Anticoagulants (Medicine) Anticoagulants (Medicine) -- Administration |
Issue Date: | 2020 |
Publisher: | Elsevier |
Citation: | Riva, N., Meli, S., Xuereb, C. B., Vella, K., Ageno, W., Makris, M., & Gatt, A. (2020). Anticoagulation control with the point-of-care INR: A retrospective pre-/post-analysis. Thrombosis Research, 196, 21-24. |
Abstract: | Vitamin K antagonists (VKA) need to be monitored with the international normalized ratio (INR), which expresses the intensity of anticoagulation. Their dosage is periodically adjusted in order to maintain the INR within an established therapeutic range, derived from the balance between the prevention of thromboembolic events and the avoidance of haemorrhagic complications. The time in therapeutic range (TTR) is an indirect measure of the anticoagulation control, and is known to correlate with the incidence of thromboembolic and bleeding events [1,2]. In order to maximise VKA benefit, the individual TTR should be at least 65–70% [3] and further increasing the TTR ≥ 80% is associated with better patient outcomes [4]. A TTR < 65% is considered “poor anticoagulation control” [5] and for these patients recent guidelines recommend interventions to improve the TTR (e.g. more frequent testing, reviewing adherence or counselling) or switching to direct oral anticoagulants (DOAC) [3]. |
URI: | https://www.um.edu.mt/library/oar/handle/123456789/87264 |
Appears in Collections: | Scholarly Works - FacM&SPat Scholarly Works - FacSoWGer |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S004938482030431X-main.pdf Restricted Access | 684.21 kB | Adobe PDF | View/Open Request a copy |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.